The increased frequency of CD61 positive intrapulmonary megakaryocytes along with the numerous thrombocyte micro-thrombi raises the question if thrombocyte aggregation inhibitor therapy might be more beneficial for advanced COVID-19 patients than the routinely employed anticoagulation therapy. Here, ITGB3 is linked to COVID-19.